← Back to Search

Protein Replacement Therapy

Prolastin-C for Chronic Pancreatitis

Phase 1 & 2
Waitlist Available
Led By Hongjun Wang, Ph.D
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 365 days
Awards & highlights

Study Summary

This trial is testing a new treatment for people with chronic pancreatitis who need their pancreas removed. The new treatment is called AAT and is being compared to the current standard of care. The trial will measure how well the two treatments work and how safe they are.

Eligible Conditions
  • Chronic Pancreatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 365 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Islet Graft Function

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Prolastin-CActive Control1 Intervention
Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Subjects will be given Saline weekly for 4 weeks.

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
933 Previous Clinical Trials
7,394,567 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,358 Previous Clinical Trials
4,315,026 Total Patients Enrolled
Hongjun Wang, Ph.DPrincipal InvestigatorMedical University of South Carolina
2 Previous Clinical Trials
19 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Hongjun Wang 2017. "Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02947087.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top